Instil Bio, Inc. · NASDAQ:TIL
Instil Bio — Investor Presentation (August 2024)
15 slides from Instil Bio's investor presentation, Aug 15, 2024
Slide 1: SYN-2510 Program Overview August 2024
SYN-2510 Program Overview August 2024 Nasdaq: TIL │ www.instilbio.com
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” "expected,” “exploring,” “future,” “intends,” “may,” “plans,” “potential,” “projects,” an
Slide 3: Potential best-in-class PD-L1xVEGF bispecific in multiple solid tumor indications
Potential best-in-class PD-L1xVEGF bispecific in multiple solid tumor indications 3 Phase 1 RightsIndication TNBC: triple-negative breast cancer; HCC: hepatocellular carcinoma; RCC: renal cell carcinoma; HR+ BC: hormone receptor positive breast cancer; NSCLC: non-small cell lung cancer IIT: investig
Slide 4: Key features of SYN-2510, bispecific PD-L1xVEGF antibody
Key features of SYN-2510, bispecific PD-L1xVEGF antibody 4 Differentiated design • VEGF trap • ADCC-enhanced Collaboration with ImmuneOnco (HKEX:1541) • In China, opportunity to leverage proof-of- concept data generation and accelerate clinical development Combination of validated oncology mechanism
Slide 5: Key Competitor Landscape
5 Key Competitor Landscape Anti-PD-L1 VHH Silenced Fc (LALA) Anti-VEGF-A Anti-VEGF-A Anti-PD-1 Anti-PD-L1 VEGF Trap ADCC- enhanced SYN-2510 BNT327 (Biotheus / BioNTech) Ivonescimab (Akeso / Summit) VEGF binding VEGF-A, VEGF-B, PLGF VEGF-A VEGF-A PD-1 or PD-L1 PD-L1 PD-L1 PD-1 ADCC Enhanced ADCC None
Slide 6: PD-1xVEGF bispecific ivonescimab has demonstrated superior outcomes when added to standard of care
PD-1xVEGF bispecific ivonescimab has demonstrated superior outcomes when added to standard of care 6 • Ivonescimab (PD-1xVEGF bispecific) + chemo outperforms chemo alone in 2L EGFRm+ NSCLC • Setting where Keytruda® failed* • Approved in 2L EGFRm NSCLC in China Source: Summit Therapeutics ASCO 2024 P
Slide 7: PD-1xVEGF bispecific ivonescimab has demonstrated superiority vs Keytruda
PD-1xVEGF bispecific ivonescimab has demonstrated superiority vs Keytruda® 7 • Ivonescimab (PD-1xVEGF bispecific) monotherapy outperforms Keytruda® monotherapy in 1L NSCLC • First randomized phase 3 trial reported of a regimen outperforming standard-of- care Keytruda® Source: Summit Therapeutics pre
Slide 8: PD-L1xVEGF bispecific BNT327 has demonstrated compelling evidence of activity in multiple solid tumors
PD-L1xVEGF bispecific BNT327 has demonstrated compelling evidence of activity in multiple solid tumors 8 • BNT327 has demonstrated high ORR % and deep responses in patients with NSCLC, small cell lung cancer (SCLC) and triple- negative breast cancer (TNBC) Source: BioNTech Q2 2024 earnings presentat
Slide 9: SYN-2510: potential best-in-class PD-L1xVEGF bispecific
SYN-2510: potential best-in-class PD-L1xVEGF bispecific 9 VEGF receptor trap binds multiple VEGF receptor ligands beyond VEGF-A for broader anti- angiogenic activity ADCC-enhanced antibody designed to induce direct killing of immune- suppressive PD-L1+ tumor cells
Slide 10: SYN-2510 binds multiple VEGF receptor ligands
SYN-2510 binds multiple VEGF receptor ligands 10 VEGF receptor trap binds multiple VEGF receptor ligands beyond VEGF-A for broader anti- angiogenic activity Avastin® SYN-2510 0.00010.001 0.01 0.1 1 10 100 1000 0 1 2 3 4 5 Concentration (nM) O D 4 5 0 VEGF-A VEGF-B VEGF-C VEGF-D PIGF 0.00010.001 0.01
Slide 11: SYN-2510 has enhanced ADCC activity
SYN-2510 has enhanced ADCC activity 11 ADCC-enhanced antibody designed to induce direct killing of immune- suppressive PD-L1+ tumor cells SYN-2510 ADCC SYN-2510 SYN-25 Atezolizumab Avastin Source: ImmuneOnco internal data on file
Slide 12: SYN-2510 achieved multiple responses in patients with prior PD-1 inhibitor during dose escalation
SYN-2510 achieved multiple responses in patients with prior PD-1 inhibitor during dose escalation 12 Thymus adenosqumous carcinomaSquamous NSCLC Squamous NSCLC Thymus adenosquamous carcinoma SYN-2510 completed dose escalation up to 20 mg/kg Q2W with a manageable safety profile and no observed dose-l
Slide 13: ImmuneOnco collaboration provides opportunity to accelerate global clinical development of SYN-2510
ImmuneOnco collaboration provides opportunity to accelerate global clinical development of SYN-2510 • Collaboration with ImmuneOnco (HKEX:1541), a Hong Kong-listed biotech developing SYN-2510/IMM2510 in China • Potential opportunities to utilize ImmuneOnco’s clinical dataset: ▪ Proof-of-concept in t
Slide 14: Recent (Q2'24 Earnings PR)
Recent Corporate Update (Q2’24 Earnings PR) 14
Slide 15: Thank you
Thank you Investor Relations (972) 499-3350 investorrelations@instilbio.com